Tags : Cancer Immunotherapies

Gilead Signs an Exclusive License Agreement with Jounce for Cancer

Shots: Jounce to receive $85M up front, $685B as clinical, regulatory, and commercial milestone payments, $35M equity investment at a premium in Jounce upon closing along with royalties on global sales of therapies including JTX-1811. The transaction is expected to be closed in H2’20 Jounce will lead the development of JTX-1811 through IND clearance, and […]Read More

Gilead Signs a Ten Years Agreement with Arcus to Co-Develop

Shots: Arcus to receive $375M including $175M up front & $200M as equity investment at a price of $33.54/ share with a premium of 35% and is eligible to receive $1.225B as in opt-in and milestones concerning its current clinical product candidates.  Gilead will support the ongoing research and development by paying $400M during the […]Read More

Gilead and Kite Sign a Three Years Agreement with oNKo-innate

Shots: oNKo-innate to receive an up front, clinical, regulatory & commercial milestones along with royalties on sales of immuno-oncology and cell therapy programs while in exchange, the company will utilize its genome-wide screening techniques and technology platform to discover novel immune cell targets enhancing NK cell anti-tumor immunity and to create NK cell therapies oNKo-innate […]Read More